{
  "document_category": "legal-advice",
  "docId": "legal-advice_72",
  "chunk_index": 18,
  "chunk_text": "Accordingly, each\nANDA is a separate and distinct asset with the professional fees paid to enhance or\nfacilitate the creation of these separate and distinct assets capitalized. Treas. Reg.\n§§ 1.263(a)-4(b)(1)(v) and -4(b)(3)(i). Treas. Reg. § 1.263(a)-4(e)(3) provides that a “transaction” for purposes of the -4\nregulations “includes a series of steps carried out as part of a single plan.” Specifically\nstating that\n(3) Transaction. For purposes of this section, the term transaction\nmeans all of the factual elements comprising an acquisition or\ncreation of an intangible and includes a series of steps carried out\nas part of a single plan. Thus, a transaction can involve more than\none invoice and more than one intangible. For example, a\npurchase of intangibles under one purchase agreement constitutes\na single transaction, notwithstanding the fact that the acquisition\ninvolves multiple intangibles and the amounts paid to facilitate the\nacquisition are capable of being allocated. Treas. Reg. § 1.263(a)-4(e)(3) (emphasis added). ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------43 See generally Generic Pharmaceutical Association Providing Extraordinary Savings for Americans. http://www.gphaonline.org/ (last visited on June 14, 2011) POSTU-139175-10 46 --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------44 ----------------------------------------------------------------------------------------------------------------------- 45 ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------44 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------45 -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 47 ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------CASE DEVELOPMENT, HAZARDS AND OTHER CONSIDERATIONS Please provide a copy of the 30-day letter, when issued, and provide a copy of\nCorporation X’s Protest, if any, when received. This writing may contain privileged information. Any unauthorized disclosure of this\nwriting may undermine our ability to protect the privileged information. If disclosure is\ndetermined to be necessary, please contact this office for our views. By: _____________________________ Marjory A. Gilbert\nIndustry Counsel (Pharmaceuticals and Biotech)\nRetailers, Food, Pharmaceuticals & Healthcare\nLarge Business & International\nOffice of Chief Counsel, IRS Attachments: Addendum -A POSTU-139175-10 48 ------------------------------------------------------------------------------------------------------------------------------In order to market or sell a new drug in the United States, the new drug must be\napproved by the Food and Drug Administration (FDA). Federal Food, Drug, and\nCosmetic Act, 21 U.S.C. § 355(a)(2010) (“No person shall introduce or deliver for\nintroduction into interstate commerce any new drug, unless an approval of an\napplication filed pursuant to subsection (b) or (j) of this section is effective with respect\nto such drug.”). 46 The term “new drug” in § 355(a) includes generic drugs. United\nStates v. Generix Drug Corporation, 460 U.S. 453, 461 (1983) (“In summary, a generic\ndrug product is a ‘drug’ within the meaning of § 201(g)(1) of the Act.”). A. New Drug Application (NDA) The 2007 Coordinated Issue Paper on taxation of drug development agreements47\nsummarizes the process for developing a new (non-generic) drug for FDA approval as\nfollows: The pharmaceutical/biotech drug development process is generally\ncomposed of four stages: Preclinical or discovery research, clinical 46 The Westlaw electronic research service has a red flag on 21 U.S.C. § 355 asserting that § 355 was\nheld unconstitutional and not severable by Florida v. United States Department of Health and Human\nServices, 2011 WL 285683 (N.D. Fla. Jan. 31, 2011), clarified and order provisionally stayed in Florida v.\nUnited States Department of Health and Human Services, 2011 WL 723117 (N.D. Fla. March 3, 2011),\naff’d in part and rev’d in part, 2011 WL 3519178 (11th Cir.)(hereinafter collectively Florida vs. HHS)."
}